Clinicopathologic analysis of ros1-rearranged non-small-cell lung cancer and proposal of a diagnostic algorithm

Heounjeong Go, Dong-Wan Kim, Donghyun Kim, Bhumsuk Keam, Tae Min Kim, Se Hoon Lee, Dae Seog Heo, Yung Jue Bang, Doohyun Chung

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

INTRODUCTION:: We sought to evaluate the clinical and pathological characteristics of patients with non-small-cell lung cancer (NSCLC) that harbored a ROS1 rearrangement. METHODS:: Four hundred fifty-one Korean patients with resected NSCLC (the resected group) were examined for ROS1 rearrangements using a tissue microarray and ROS1 fluorescence in situ hybridization and analyzed for clinical and pathological features. Sixty-four patients with advanced pulmonary adenocarcinoma with no known oncogenic aberrations (the advanced group) were also screened for ROS1 rearrangements. RESULTS:: Of the 451 consecutive patients from the resected group, ROS1 rearrangements were detected in eight cases (1.8%). In the advanced group, an additional eight patients (12.5%) were identified as harboring ROS1 rearrangements. ROS1 rearrangement was detected exclusively in adenocarcinomas and occurred more frequently in women than in men. With the exception of one patient with an EGFR deletion mutation in exon 19, ROS1-positive adenocarcinomas in all patients revealed no alterations in ALK, EGFR, KRAS, or MET genes. Most ROS1-rearranged tumors showed solid and papillary patterns. CONCLUSIONS:: ROS1 rearrangements were detected in 1.8% of patients with resected NSCLC and were detected exclusively in adenocarcinomas, which is similar to the frequency detected in non-Asian patients. We suggest that ROS1 screening in adenocarcinoma patients with no known oncogenic aberrations is an effective strategy to find ROS1 rearrangements in NSCLC.

Original languageEnglish
Pages (from-to)1445-1450
Number of pages6
JournalJournal of Thoracic Oncology
Volume8
Issue number11
DOIs
StatePublished - 1 Nov 2013

Fingerprint

Non-Small Cell Lung Carcinoma
Adenocarcinoma
Sequence Deletion
Fluorescence In Situ Hybridization
Exons

Keywords

  • Clinicopathology
  • Fluorescence in situ hybridization
  • Molecular enrichment strategy
  • Pulmonary adenocarcinoma
  • ROS1

Cite this

@article{f225f10948074a7db3c27214487b9da0,
title = "Clinicopathologic analysis of ros1-rearranged non-small-cell lung cancer and proposal of a diagnostic algorithm",
abstract = "INTRODUCTION:: We sought to evaluate the clinical and pathological characteristics of patients with non-small-cell lung cancer (NSCLC) that harbored a ROS1 rearrangement. METHODS:: Four hundred fifty-one Korean patients with resected NSCLC (the resected group) were examined for ROS1 rearrangements using a tissue microarray and ROS1 fluorescence in situ hybridization and analyzed for clinical and pathological features. Sixty-four patients with advanced pulmonary adenocarcinoma with no known oncogenic aberrations (the advanced group) were also screened for ROS1 rearrangements. RESULTS:: Of the 451 consecutive patients from the resected group, ROS1 rearrangements were detected in eight cases (1.8{\%}). In the advanced group, an additional eight patients (12.5{\%}) were identified as harboring ROS1 rearrangements. ROS1 rearrangement was detected exclusively in adenocarcinomas and occurred more frequently in women than in men. With the exception of one patient with an EGFR deletion mutation in exon 19, ROS1-positive adenocarcinomas in all patients revealed no alterations in ALK, EGFR, KRAS, or MET genes. Most ROS1-rearranged tumors showed solid and papillary patterns. CONCLUSIONS:: ROS1 rearrangements were detected in 1.8{\%} of patients with resected NSCLC and were detected exclusively in adenocarcinomas, which is similar to the frequency detected in non-Asian patients. We suggest that ROS1 screening in adenocarcinoma patients with no known oncogenic aberrations is an effective strategy to find ROS1 rearrangements in NSCLC.",
keywords = "Clinicopathology, Fluorescence in situ hybridization, Molecular enrichment strategy, Pulmonary adenocarcinoma, ROS1",
author = "Heounjeong Go and Dong-Wan Kim and Donghyun Kim and Bhumsuk Keam and Kim, {Tae Min} and Lee, {Se Hoon} and Heo, {Dae Seog} and Bang, {Yung Jue} and Doohyun Chung",
year = "2013",
month = "11",
day = "1",
doi = "10.1097/JTO.0b013e3182a4dd6e",
language = "English",
volume = "8",
pages = "1445--1450",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "11",

}

TY - JOUR

T1 - Clinicopathologic analysis of ros1-rearranged non-small-cell lung cancer and proposal of a diagnostic algorithm

AU - Go, Heounjeong

AU - Kim, Dong-Wan

AU - Kim, Donghyun

AU - Keam, Bhumsuk

AU - Kim, Tae Min

AU - Lee, Se Hoon

AU - Heo, Dae Seog

AU - Bang, Yung Jue

AU - Chung, Doohyun

PY - 2013/11/1

Y1 - 2013/11/1

N2 - INTRODUCTION:: We sought to evaluate the clinical and pathological characteristics of patients with non-small-cell lung cancer (NSCLC) that harbored a ROS1 rearrangement. METHODS:: Four hundred fifty-one Korean patients with resected NSCLC (the resected group) were examined for ROS1 rearrangements using a tissue microarray and ROS1 fluorescence in situ hybridization and analyzed for clinical and pathological features. Sixty-four patients with advanced pulmonary adenocarcinoma with no known oncogenic aberrations (the advanced group) were also screened for ROS1 rearrangements. RESULTS:: Of the 451 consecutive patients from the resected group, ROS1 rearrangements were detected in eight cases (1.8%). In the advanced group, an additional eight patients (12.5%) were identified as harboring ROS1 rearrangements. ROS1 rearrangement was detected exclusively in adenocarcinomas and occurred more frequently in women than in men. With the exception of one patient with an EGFR deletion mutation in exon 19, ROS1-positive adenocarcinomas in all patients revealed no alterations in ALK, EGFR, KRAS, or MET genes. Most ROS1-rearranged tumors showed solid and papillary patterns. CONCLUSIONS:: ROS1 rearrangements were detected in 1.8% of patients with resected NSCLC and were detected exclusively in adenocarcinomas, which is similar to the frequency detected in non-Asian patients. We suggest that ROS1 screening in adenocarcinoma patients with no known oncogenic aberrations is an effective strategy to find ROS1 rearrangements in NSCLC.

AB - INTRODUCTION:: We sought to evaluate the clinical and pathological characteristics of patients with non-small-cell lung cancer (NSCLC) that harbored a ROS1 rearrangement. METHODS:: Four hundred fifty-one Korean patients with resected NSCLC (the resected group) were examined for ROS1 rearrangements using a tissue microarray and ROS1 fluorescence in situ hybridization and analyzed for clinical and pathological features. Sixty-four patients with advanced pulmonary adenocarcinoma with no known oncogenic aberrations (the advanced group) were also screened for ROS1 rearrangements. RESULTS:: Of the 451 consecutive patients from the resected group, ROS1 rearrangements were detected in eight cases (1.8%). In the advanced group, an additional eight patients (12.5%) were identified as harboring ROS1 rearrangements. ROS1 rearrangement was detected exclusively in adenocarcinomas and occurred more frequently in women than in men. With the exception of one patient with an EGFR deletion mutation in exon 19, ROS1-positive adenocarcinomas in all patients revealed no alterations in ALK, EGFR, KRAS, or MET genes. Most ROS1-rearranged tumors showed solid and papillary patterns. CONCLUSIONS:: ROS1 rearrangements were detected in 1.8% of patients with resected NSCLC and were detected exclusively in adenocarcinomas, which is similar to the frequency detected in non-Asian patients. We suggest that ROS1 screening in adenocarcinoma patients with no known oncogenic aberrations is an effective strategy to find ROS1 rearrangements in NSCLC.

KW - Clinicopathology

KW - Fluorescence in situ hybridization

KW - Molecular enrichment strategy

KW - Pulmonary adenocarcinoma

KW - ROS1

UR - http://www.scopus.com/inward/record.url?scp=84886545743&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e3182a4dd6e

DO - 10.1097/JTO.0b013e3182a4dd6e

M3 - Article

C2 - 24128715

AN - SCOPUS:84886545743

VL - 8

SP - 1445

EP - 1450

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 11

ER -